Boehringer Ingelheim Press Releases This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations
• A single 5g dose of idarucizumab immediately reversed the anticoagulant effect of dabigatran in all patients evaluated • Results based on analyses of high-risk patients from RE-VERSE AD™ study • Data presented today at ACC 2016 Scientific Session and Expo (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - April 1, 2016 Category: Research Source Type: news

The 4WARD Coalition™ Launches AFib4WARD.com to Encourage Shared Decision Making Between AFib Patients and Healthcare Providers
• AFib4WARD.com is designed to help patients better understand atrial fibrillation (AFib) and make informed treatment decisions with their healthcare providers (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - March 30, 2016 Category: Research Source Type: news

Propeller Health and Boehringer Ingelheim Announce New Partnership Focused on Improving Adherence and Care Management for People Living with COPD and Asthma
First-of-its-kind commercial partnership between pharmaceutical and digital health companies in respiratory medicine (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - March 22, 2016 Category: Research Source Type: news

Boehringer Ingelheim Cares Foundation and AmeriCares Launch Health Coach Program for the Uninsured
Coaches Will Help Empower Patients to Make Healthy Lifestyle Changes (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - March 14, 2016 Category: Research Source Type: news

Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate), Now Stocked in More Than 2,200 Hospitals
• New PRAXBIND.com tool enables physicians and patients to quickly locate local institutions where PRAXBIND is available (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - March 7, 2016 Category: Research Source Type: news

New Analyses: Adding SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Effective for Uncontrolled Asthma – Regardless of Allergy Subtype
• SPIRIVA® RESPIMAT® shown effective in the broad range of asthma patients studied who continued to experience symptoms despite taking other asthma maintenance therapies • New analyses show improved lung function* and asthma symptom control and reduced asthma exacerbations† for patients with allergic asthma (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - March 6, 2016 Category: Research Source Type: news

SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
SPIRIVA RESPIMAT is the first new class of inhaled medicine approved in over 10 years for the treatment of asthmaSPIRIVA RESPIMAT works differently than other medicines to help people with asthma breathe better (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - February 2, 2016 Category: Research Source Type: news

Boehringer Ingelheim’s Gilotrif® (afatinib) demonstrated superiority to Iressa® (gefitinib) in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer
• Results of global Phase IIb LUX-Lung 7 trial demonstrate afatinib is superior in reducing the risk of lung cancer progression and the risk of treatment failure both by 27% compared to gefitinib • More patients on afatinib were free of cancer growth 18 and 24 months after the start of treatment (27% vs 15% and 18% vs 8%, respectively) • The overall frequency of patients experiencing serious adverse events and discontinuing treatment due to adverse events was similar in both arms (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - January 26, 2016 Category: Research Source Type: news

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - January 24, 2016 Category: Research Source Type: news